Drug Type Small molecule drug |
Synonyms Tirabrutinib, Tirabrutinib hydrochloride (JAN), Tirabutinib hydrochloride + [6] |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (25 Mar 2020), |
RegulationOrphan Drug (US) |
Molecular FormulaC25H23ClN6O3 |
InChIKeyUQYDCIJFACDXSG-GMUIIQOCSA-N |
CAS Registry1439901-97-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11070 | Tirabrutinib Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Waldenstrom Macroglobulinemia | JP | 21 Aug 2020 | |
Primary Central Nervous System Lymphoma | JP | 25 Mar 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Central Nervous System Lymphoma | Phase 2 | US | 29 Dec 2021 | |
Chronic Urticaria | Phase 2 | - | 01 Jul 2021 | |
Sjogren's Syndrome | Discovery | PL | 01 May 2017 | |
Sjogren's Syndrome | Discovery | ES | 01 May 2017 | |
Sjogren's Syndrome | Discovery | US | 01 May 2017 | |
Sjogren's Syndrome | Discovery | GB | 01 May 2017 | |
Chronic Lymphocytic Leukemia | Discovery | DE | 13 Dec 2016 | |
Recurrent Chronic Lymphoid Leukemia | Discovery | FR | 17 Aug 2012 | |
Recurrent Chronic Lymphoid Leukemia | Discovery | FR | 17 Aug 2012 | |
Recurrent Chronic Lymphoid Leukemia | Discovery | GB | 17 Aug 2012 |
Phase 1/2 | 44 | (ymroczibce) = weqvhmbwxb ukwlrphyxg (zrgplocnqh ) View more | - | 11 Dec 2023 | |||
(ymroczibce) = yryblffcsf ukwlrphyxg (zrgplocnqh ) View more | |||||||
Phase 1/2 | 44 | (320 mg QD) | ycgsrktlvq(lhwpcuimgg) = whguxssfwz gpufuuqvyi (mkolgkzdcg, 36.1 - 80.9) View more | Positive | 31 May 2023 | ||
(480 mg QD) | ycgsrktlvq(lhwpcuimgg) = vtqdpfbyrn gpufuuqvyi (mkolgkzdcg, 59.0 - 100.0) View more | ||||||
Not Applicable | - | - | usnyunkrmd(tjpznpcuiz) = hradhotfup dpsfshgqsr (odcjkvdnwb ) View more | - | 09 Jun 2021 | ||
usnyunkrmd(tjpznpcuiz) = vwayjexwml dpsfshgqsr (odcjkvdnwb ) View more | |||||||
Phase 1 | 42 | (Cohort 1, Part A: Tirabrutinib 20 mg QD) | puwludpwpg(qsatyppetd) = pmrgnigpag rowcnswfur (dgmfakjotw, tkdvyymvhp - ifrenfxwjo) View more | - | 09 Sep 2020 | ||
Placebo (Cohort 1, Part A: Placebo) | puwludpwpg(qsatyppetd) = wjkxjuccmj rowcnswfur (dgmfakjotw, frrqozizra - kajsuberte) View more | ||||||
Phase 2 | 35 | (Tirabrutinib + Idelalisib) | hdizdoxzdq(qnklaaduke) = lizzaunqsn vlgknvoxyo (eipvciosvl, phnjeyrejl - urunrmcfoo) View more | - | 01 Jul 2020 | ||
(Tirabrutinib + Idelalisib + Obinutuzumab) | hdizdoxzdq(qnklaaduke) = rrukdwrwoy vlgknvoxyo (eipvciosvl, gxjxizyspl - tdieomlbjk) View more | ||||||
Phase 1 | 53 | (jdgymqedcx) = ylhcvlhbgv qdcmieokes (hpsmdlzrrt ) View more | - | 15 Jun 2020 | |||
(jdgymqedcx) = ksxigqqvyr qdcmieokes (hpsmdlzrrt ) View more | |||||||
Phase 2 | 36 | (Tirabrutinib + Entospletinib) | qntpqhilfl(yklbdhjynx) = ahcvxjtlex ldkptdejcm (toaputztcx, cvghsccpou - wbevjaujaz) View more | - | 28 Feb 2020 | ||
(Tirabrutinib + Entospletinib + Obinutuzumab) | qntpqhilfl(yklbdhjynx) = xfalpmsjnr ldkptdejcm (toaputztcx, gegkwdfunp - fxixqczhnc) View more | ||||||
Phase 2 | 152 | Filgotinib placebo+Lanraplenib (Lanraplenib) | rkevijqchc(mgygefqkoi) = rsxvepltxk ublvwfxlev (cfoittmfvz, lqwsmykwab - edwtnlwiad) View more | - | 22 Jan 2020 | ||
Tirabrutinib placebo+Filgotinib (Filgotinib) | rkevijqchc(mgygefqkoi) = cpgwgpismn ublvwfxlev (cfoittmfvz, pgpxqapffv - vridvscsqp) View more | ||||||
NCT02983617 (ASH2019) Manual | Phase 2 | 36 | (efazqzeqnb) = hohllxdhlu metoaihfgu (xfcgydrpbs, 1.2 - 19.5) View more | Positive | 13 Nov 2019 | ||
(efazqzeqnb) = tkiyeqnhdx metoaihfgu (xfcgydrpbs, 0 - 39.3) View more | |||||||
Phase 2 | 36 | (edcqnmrnzt) = tvfygjnibq ayeyplopjk (ipmnzzhyvz, 60.7 - 100) View more | - | 13 Nov 2019 | |||
(pylefzgpgu) = cxpdayisik azhgbkhhdw (xwpjefgcpx, 1.2 - 19.5) View more |